Human IgG is the most abundant glycoprotein in serum and is crucial for protective
immunity. In addition to conserved IgG Fc glycans,∼ 15–25% of serum IgG contains glycans …

Antibodies are highly potent therapeutic scaffolds with more than a hundred different
products approved on the market. Successful development of antibody-based drugs …

Therapeutic mAbs must not only bind to their target but must also be free from
“developability issues” such as poor stability or high levels of aggregation. While small …

The use of biopharmaceuticals dates from the 19th century and within 5-10 years, up to 50%
of all drugs in development will be biopharmaceuticals. In the 1980s, the biopharmaceutical …

Protein aggregation in biotherapeutics has been identified to increase immunogenicity,
leading to immune-mediated adverse effects, such as severe allergic responses including …

Protein aggregation is a hallmark of a growing number of human disorders and constitutes a
major bottleneck in the manufacturing of therapeutic proteins. Therefore, there is a strong …

Increasing attention has been paid to developability assessment with the understanding that
thorough evaluation of monoclonal antibody lead candidates at an early stage can avoid …

N-glycosylation is one of major post-translational modifications in nature, and it is essential
for protein structure and function. As hydrophilic moieties of glycoproteins, N-glycans play …

Over thousands of years, modernization could be predicted for the use of microorganisms in
the production of foods and beverages. However, the current accelerated pace of new food …

Protein instability leads to reversible self-association and irreversible aggregation which is a
major concern for developing new biopharmaceutical leads. Protein solution behaviour is …